Wieland Douglas Scott 4
4 · CYTRX CORP · Filed Jul 6, 2009
Insider Transaction Report
Form 4
CYTRX CORPCYTR
Wieland Douglas Scott
Sr. VP - Drug Development
Transactions
- Award
Stock Option (right to buy)
2009-07-01+100,000→ 100,000 totalExercise: $1.15Exp: 2017-05-22→ Common Stock (100,000 underlying) - Award
Stock Option (right to buy)
2009-07-01+25,000→ 25,000 totalExercise: $1.15Exp: 2017-12-04→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2009-07-01−25,000→ 0 totalExercise: $3.61Exp: 2017-12-04→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2009-07-01−100,000→ 0 totalExercise: $4.08Exp: 2017-05-22→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 30, 2007 and provided for vesting in three equal annual installments beginning May 30, 2008. The replacement option provides vesting two-thirds of the option on December 31, 2009, and vesting one-third of the option on May 30, 2010, providing the Reporting Person remains in continuous employ of Issuer.
- [F2]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 6, 2007 and provided for vesting in three equal annual installments beginning December 6, 2008. The replacement option provides vesting one-third of the option on December 31, 2009, vesting one-third on December 6, 2010, and vesting one-third on December 6, 2011, provided Reporting Person remains in continuous employ of Issuer.